logo

For the Inventor, By the Inventor

Mainz, Germany

Biontech Se


USPTO Granted Patents = 74



Trademarks = 20

Forward Citations = 48

Loading Chart...
Loading Chart...

151 inventors (with patents filed for the assignee):

goldMedal Ugur Sahin (59 out of 195 patents)

silverMedal Friederike Gieseke (14 out of 19 patents)

bronzeMedal David Satijn (13 out of 44 patents)

4.  Alexander Muik (13 out of 15 patents)

5.  Paul Parren (12 out of 135 patents)

6.  Isil Altintas (12 out of 20 patents)

7.  Mustafa Diken (12 out of 21 patents)

8.  Heinrich Haas (11 out of 21 patents)

9.  Sebastian Kreiter (11 out of 27 patents)

10.  Rik Rademaker (8 out of 32 patents)

11.  Andreas Kuhn (7 out of 10 patents)

12.  Kerstin Walzer (6 out of 7 patents)

13.  Tim Beissert (6 out of 12 patents)

14.  Sebastian Hörner (5 out of 5 patents)

15.  Annette Vogel (5 out of 5 patents)


Core Competencies:
RNA
Cancer Treatment
Immunogenicity
Liposomal Formulations
Tumor Antigens
Multispecific Antibodies
Vaccine Development
Therapeutic RNA
Binding Agents
RNA Formulation
Gene Expression
T Cell Activation

74 patents:

1. 12734233 - THERAPEUTIC RNA FOR HPV-POSITIVE CANCER (2026-09-15),
2. 12667621 - RNA FORMULATIONS SUITABLE FOR THERAPY (2026-06-30),
3. 12643930 - IL2 Agonists (2026-06-02),
4. 12637515 - BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF (2026-05-26),
5. 12599660 - THERAPEUTIC RNA FOR HPV-POSITIVE CANCER (2026-04-14),
6. 12522640 - IL2 Agonists (2026-01-13),
7. 12516333 - 3'-UTR SEQUENCES FOR STABILIZATION OF RNA (2026-01-06),
8. 12516104 - Compositions and Methods for Diagnosis and Treatment of Cancer (2026-01-06),
9. 12460198 - Method for reducing immunogenicity of RNA (2025-11-04),
10. 12433911 - Preparation and storage of liposomal RNA formulations suitable for therapy (2025-10-07),
11. 12421319 - Binding agents that bind OX40 (CD134) and method of use thereof to treat disease (2025-09-23),
12. 12419965 - RNA particles comprising polysarcosine (2025-09-23),
13. 12410258 - Antibodies capable of binding to OX40, variants thereof and uses thereof (2025-09-09),
14. 12410221 - Tumor antigens for determining cancer therapy (2025-09-09),
15. 12398214 - Binding agents binding to EpCAM and CD137 (2025-08-26),
BioNTech SE is a German biotechnology company that specializes in the development and manufacture of immunotherapies for the treatment of cancer and other diseases. Founded in 2008, BioNTech has emerged as a leading provider of innovative precision medicine for personalized cancer immunotherapy. The company combines cutting-edge technologies such as mRNA therapy and individualized neoepitope-targeting vaccines to develop novel treatment approaches. BioNTech is committed to revolutionizing the treatment of cancer and aims to achieve long-lasting, durable remissions for patients.
This text is generated by artificial intelligence and may not be accurate.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Biontech Se
74 Patents

#5 in Mainz

#774 in Germany

#10,105 in the World

Mainz, DE
Mainz, Germany

Biontech Se

Forward Citations = 48

151 inventors:

goldMedal Ugur Sahin (59 out of 195 patents)

silverMedal Friederike Gieseke (14 out of 19 patents)

bronzeMedal David Satijn (13 out of 44 patents)

4.  Alexander Muik (13 out of 15 patents)

5.  Paul Parren (12 out of 135 patents)

Please report any incorrect information to [email protected]
Loading…